Also known as: Alendronate sodium
Alendronic acid is indicated for:
Irrespective of gender only Adults (18 years old or older)
Alendronic acid is indicated for the treatment of:
For this indication, the medical literature mentions below treatments (click for details):
Active ingredient Alendronic acid is contraindicated in the following cases:
Alendronate is not recommended for patients with renal impairment where creatinine clearance is less than 35 ml/min, due to lack of experience.
It is unknown whether alendronate/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Alendronic acid should not be used during breast-feeding.
Aledronic acid should not be used during pregnancy. There are no adequate data from the use of aledronic acid in pregnant women. Animal studies do not indicate direct harmful effects with respect to pregnancy, embryonal/fetal development, or postnatal development. Aledronic acid given during pregnancy in rats caused dystocia related to hypocalcemia.
Alendronic acid is contraindicated in inability to stand or sit upright for at least 30 minutes.
Alendronic acid is contraindicated in hypocalcaemia.
Alendronic acid is contraindicated in abnormalities of the oesophagus and other factors which delay oesophageal emptying such as stricture or achalasia.